




Instance: composition-en-e7c357e85455d1fe389fd3b297f16867
InstanceOf: CompositionUvEpi
Title: "Composition for axumin Package Leaflet"
Description:  "Composition for axumin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc8dd0ed09610078bf6d788aa5df84324)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - axumin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Axumin is and what it is used for  </li>
<li>What you need to know before you use Axumin </li>
<li>How to use Axumin </li>
<li>Possible side effects  </li>
<li>How to store Axumin </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What axumin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What axumin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This medicine is a radiopharmaceutical product for diagnostic use only. </p>
<p>Axumin contains the active substance fluciclovine (18F) and is given so that doctors can perform a 
special type of scan called a positron emission tomography (PET) scan. If you have previously had 
treatment for prostate cancer and information from other tests (e.g. prostate specific antigen, PSA) 
indicates that the cancer may have returned, an Axumin PET scan can help your doctor find the 
locations where the cancer has come back.  </p>
<p>You should discuss the results of the test with the doctor that requested the scan. </p>
<p>The use of Axumin does involve exposure to small amounts of radioactivity. Your doctor and the 
nuclear medicine doctor have considered that the benefit of this procedure with the 
radiopharmaceutical outweighs the risk of being exposed to radiation.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Axumin must not be used 
- if you are allergic to fluciclovine (18F) or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions<br />
Talk to your nuclear medicine doctor before you are given Axumin if you:</p>
<ul>
<li>have kidney problems </li>
<li>are on a low sodium diet (see section "Axumin contains sodium"). </li>
</ul>
<p>Before administration of Axumin you:</p>
<ul>
<li>should avoid exercise for at least a day before the Axumin scan. </li>
<li>should not eat or drink for at least 4 hours before the scan (you can take your usual medicines 
with small amounts of water).   </li>
<li>may urinate at the latest 60 minutes before the Axumin injection and you should avoid urination 
until after the scan has been completed. </li>
</ul>
<p>Children and adolescents 
Talk to your nuclear medicine doctor if you are under 18 years old. Axumin is not intended for use in 
children and adolescents aged under 18 years. </p>
<p>Other medicines and Axumin<br />
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other 
medicines since they may interfere with the interpretation of the images. </p>
<p>Pregnancy and breast-feeding 
This medicine is not indicated for use in women. </p>
<p>Driving and using machines<br />
It is considered unlikely that Axumin will affect your ability to drive or to use machines. </p>
<p>Axumin contains sodium 
This medicine contains up to 39 mg sodium (main component of cooking/table salt) in each dose. This 
is equivalent to 2% of the recommended maximum daily dietary intake of sodium for an adult.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of radiopharmaceutical products.<br />
Axumin will only be used in specially controlled areas. This medicine will only be handled and given 
to you by people who are trained and qualified to use it safely. These persons will take special care for 
the safe use of this medicine and will keep you informed of their actions.  </p>
<p>The nuclear medicine doctor supervising the procedure will decide on the quantity of Axumin to be 
used in your case. It will be the smallest quantity necessary to get the desired information. The 
quantity to be administered usually recommended for an adult is 370 MBq (megabecquerel, the unit 
used to express radioactivity). </p>
<p>Administration of Axumin and conduct of the procedure<br />
Axumin is administered intravenously as an injection into your vein followed by a flush of sodium 
chloride solution to ensure that you receive the full dose.  </p>
<p>One injection is usually sufficient to conduct the test that your doctor needs. </p>
<p>Duration of the procedure<br />
Your nuclear medicine doctor will inform you about the usual duration of the procedure. The scan will 
usually start approximately 5 minutes after the Axumin injection is given. </p>
<p>After administration of Axumin you should:</p>
<ul>
<li>avoid any close contact with young children and pregnant women for the 12 hours following 
the injection </li>
<li>urinate frequently in order to eliminate the product from your body. </li>
</ul>
<p>The nuclear medicine doctor will inform you if you need to take any other special precautions after 
receiving this medicine. Contact your nuclear medicine doctor if you have any questions.  </p>
<p>If you have been given more Axumin than you should 
An overdose is unlikely because you will only receive a single dose of Axumin precisely controlled by 
the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, you will 
receive the appropriate treatment. In particular, the nuclear medicine doctor in charge of the procedure 
may provide ways to increase the passing of urine and stools in order to facilitate the removal of 
radioactivity from your body. </p>
<p>Should you have any further question on the use of Axumin, please ask your nuclear medicine doctor 
who supervises the procedure. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. In clinical 
studies side effects were reported by less than 1 in 100 patients given the medicine. </p>
<p>The following side effects of Axumin are common (may affect up to 1 in 100 people).<br />
- Altered taste in the mouth, altered sense of smell, pain or rash at the site of injection. </p>
<p>This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk 
of cancer and hereditary abnormalities.  </p>
<p>Reporting of side effects 
If you get any side effects talk to your nuclear medicine doctor. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored under the responsibility of the 
specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national 
regulation on radioactive materials.  </p>
<p>The following information is intended for the specialist only.  </p>
<p>Axumin must not be used after the expiry date which is stated on the shield label after EXP. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Axumin contains<br />
- The active substance is fluciclovine (18F).<br />
Axumin 1,600 MBq/mL solution for injection<br />
Each mL of solution contains 1,600 MBq fluciclovine (18F) at date and time of calibration 
(ToC).<br />
The activity per vial ranges from 1,600 MBq to 16,000 MBq at the date and ToC. 
Axumin 3,200 MBq/mL solution for injection<br />
Each mL of solution contains 3,200 MBq fluciclovine (18F) at date and ToC.The activity per vial 
ranges from 3,200 MBq to 32,000 MBq at the date and ToC. 
- The other ingredients are sodium citrate, concentrated hydrochloric acid, sodium hydroxide, 
water for injections (see section 2 "Axumin contains sodium") </p>
<p>What Axumin looks like and contents of the pack 
Axumin is a clear, colourless solution stored in a 10 mL or 15 mL glass vial. </p>
<p>Axumin 1,600 MBq/mL solution for injection 
Each multidose vial contains 1 to 10 mL of solution, corresponding to 1,600 to 16,000 MBq at the date 
and ToC. </p>
<p>Axumin 3,200 MBq/mL solution for injection 
Each multidose vial contains 1 to 10 mL of solution, corresponding to 3,200 to 32,000 MBq at the date 
and ToC.  </p>
<p>Pack size: 1 vial. </p>
<p>Marketing Authorisation Holder<br />
Blue Earth Diagnostics Ireland Ltd, 6th Floor, 2 Grand Canal Square, Dublin 2,  reland </p>
<p>Manufacturer 
Seibersdorf Labor GmbH, 2444 Seibersdorf, Austria. </p>
<p>Norsk medisinsk syklotronsenter AS, 0372 Oslo, Norway. </p>
<p>Advanced Accelerator Applications Molecular Imaging France S.A.S., 13005 Marseille, France </p>
<p>Nucleis SA, 4000 Li ge, Belgium </p>
<p>Advanced Accelerator Applications Molecular Imaging Italy S.r.l., 47014, Meldola (FC), Italy </p>
<p>Advanced Accelerator Applications Molecular Imaging France S.A.S., 92210 Saint-Cloud, France </p>
<p>Synektik Pharma Sp. z o.o., 96-320 Mszczon w, Poland </p>
<p>Advanced Accelerator Applications Molecular Imaging Ib rica, S.L.U. 08950, Esplugues de 
Llobregat, Spain </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-e7c357e85455d1fe389fd3b297f16867
InstanceOf: CompositionUvEpi
Title: "Composition for axumin Package Leaflet"
Description:  "Composition for axumin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc8dd0ed09610078bf6d788aa5df84324)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - axumin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at bruge Axumin </li>
<li>Sådan skal du bruge Axumin </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What axumin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What axumin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Axumin er et radioaktivt lægemiddel, der kun er til diagnostisk brug. </p>
<p>Axumin indeholder det aktive stof fluciclovin (18F). Axumin indgives, så der kan udføres en såkaldt 
positron-emission tomografi (PET)-scanning. Hvis du tidligere er blevet behandlet for prostatakræft, 
og hvis andre testresultater (f.eks. værdierne for prostataspecifikt antigen) viser, at kræften kan være 
vendt tilbage, kan en PET-scanning med Axumin hjælpe med at finde de steder, hvor kræften er vendt 
tilbage.  </p>
<p>Du skal drøfte resultaterne af scanningen med den læge, der har bestilt den. </p>
<p>Brug af Axumin indebærer, at du udsættes for små mængder radioaktivitet. Kræftlægen og den 
nuklearmedicinske læge har vurderet, at fordelen for dig ved at få dette radioaktive lægemiddel 
opvejer din risiko ved at blive udsat for stråling.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Axumin 
- hvis du er allergisk over for fluciclovin (18F) eller et af de øvrige indholdsstoffer i Axumin 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler<br />
Tal med den nuklearmedicinske læge, før du får Axumin, hvis du:</p>
<ul>
<li>har nyreproblemer </li>
<li>får en kost med et lavt indhold af natrium (se afsnittet "Axumin indeholder natrium"). </li>
</ul>
<p>Før du får Axumin:</p>
<ul>
<li>skal du undgå motion i mindst et døgn før Axumin-scanningen </li>
<li>må du ikke spise og drikke i mindst 4 timer inden scanningen (du må dog gerne tage din 
sædvanlige medicin med lidt vand). </li>
<li>kan du lade vandet senest 60 minutter inden injektionen af Axumin. Du skal desuden undgå at 
lade vandet, indtil scanningen er fuldført.  </li>
</ul>
<p>Børn og unge 
Du skal tale med den nuklearmedicinske læge, hvis du er under 18 år. Axumin er ikke beregnet til 
børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Axumin<br />
Fortæl det altid til den nuklearmedicinske læge, hvis du tager anden medicin for nylig har taget/brugt 
anden medicin eller planlægger at tage/bruge anden medicin, da andre lægemidler kan have betydning 
for fortolkningen af billederne. </p>
<p>Graviditet og amning 
Dette lægemiddel er ikke beregnet til brug hos kvinder. </p>
<p>Trafik- og arbejdssikkerhed<br />
Axumin påvirker sandsynligvis ikke evnen til færdes sikkert i trafikken eller betjene maskiner. </p>
<p>Axumin indeholder natrium 
Dette lægemiddel indeholder op til 39 mg natrium (hoved komponent af madlavnings-/bordsalt) i hver 
dosis. Dette svarer til 2% af den anbefalede maximale daglige indtagelse af natrium til en voksen.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der er en streng lovgivning vedrørende anvendelse, håndtering og bortskaffelse af radioaktive 
lægemidler.<br />
Axumin vil kun blive brugt i særligt kontrollerede områder. Lægemidlet vil kun blive håndteret og 
givet til dig af kvalificerede personer, der er uddannet til at bruge det sikkert. De vil være særligt 
omhyggelige med at sikre forsvarlig brug af lægemidlet, og de vil fortælle dig, hvad der sker 
undervejs.  </p>
<p>Den nuklearmedicinske læge med ansvar for undersøgelsen afgør, hvor meget Axumin der skal bruges 
i dit tilfælde. Mængden vil være så lille som mulig til at opnå de ønskede data. Den sædvanligt 
anbefalede mængde til en voksen er 370 MBq (mega-becquerel er den enhed, der anvendes til at 
udtrykke radioaktivitet). </p>
<p>Indgivelse af Axumin og gennemførelse af undersøgelsen<br />
Axumin administreres intravenøst som en indsprøjtning i en blodåre efterfulgt af gennemskylning med 
natriumchlorid-injektionsvæske (saltvand) for at sikre, at du får hele dosis.  </p>
<p>Det er normalt nok med én injektion til den undersøgelse, som lægen skal foretage. </p>
<p>Undersøgelsens varighed<br />
Den nuklearmedicinske læge vil fortælle dig, hvor lang tid undersøgelsen tager. Scanningen 
påbegyndes typisk ca. 5 minutter efter injektion af Axumin. </p>
<p>Efter Axumin-scanningen skal du gøre følgende:</p>
<ul>
<li>undgå enhver tæt kontakt med børn og gravide kvinder i 12 timer efter injektionen </li>
<li>sørg for at lade vandet hyppigt, så lægemidlet kan komme ud af kroppen igen. </li>
</ul>
<p>Den nuklearmedicinske læge vil fortælle dig, om du skal tage andre særlige forholdsregler, når du har 
fået dette lægemiddel. Spørg den nuklearmedicinske læge, hvis der er noget, du er i tvivl om.  </p>
<p>Hvis du har fået for meget Axumin 
Det er ikke sandsynligt, at du får for meget Axumin, da du kun får en enkelt dosis, der er nøje fastsat 
af den nuklearmedicinske læge, der har ansvar for undersøgelsen. Hvis det alligevel skulle ske, vil du 
få den nødvendige behandling. Den nuklearmedicinske læge kan f.eks. give dig lægemidler, der 
fremmer vandladning og afføring, så radioaktiviteten kommer hurtigere ud af kroppen. </p>
<p>Spørg den nuklearmedicinske læge, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. I 
kliniske studier er der rapporteret bivirkninger hos mindre end 1 ud af 100 patienter, der har fået 
lægemidlet. </p>
<p>Følgende bivirkninger ved Axumin er -ikke almindelig (kan forekomme hos op til 1 ud af 
100 behandlede).<br />
- Ændret smag i munden, ændret lugtesans, smerter eller udslæt på injektionsstedet. </p>
<p>Dette radioaktive lægemiddel afgiver små mængder ioniserende stråling, der er forbundet med en 
meget lille risiko for kræft og arvelige abnormiteter.  </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med den nuklearmedicinske læge. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store axumin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store axumin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du vil ikke blive bedt om at opbevare lægemidlet. Dette lægemiddel opbevares på passende vis under 
speciallægens ansvar. Opbevaring af radioaktive lægemidler vil ske i overensstemmelse med den 
nationale lovgivning for radioaktive materialer.  </p>
<p>Nedenstående oplysninger er til læger og sundhedspersonale:  </p>
<p>Axumin må ikke anvendes efter den udløbsdato, der står efter EXP på etiketten på afskærmningen.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Axumin indeholder:</p>
<ul>
<li>Aktivt stof: fluciclovin (18F).<br />
Axumin 1.600 MBq/ml injektionsvæske, opløsning<br />
En ml injektionsvæske indeholder 1.600 MBq fluciclovin (18F) på datoen og tidspunktet for 
kalibrering (ToC). Aktiviteten pr. hætteglas ligger mellem 1.600 MBq og 16.000 MBq på 
datoen og ToC. 
Axumin 3.200 MBq/ml injektionsvæske, opløsning<br />
En ml injektionsvæske indeholder 3.200 MBq fluciclovin (18F) på datoen og ToC. Aktiviteten 
pr. hætteglas ligger mellem 3.200 MBq og 32.000 MBq på datoen og ToC. </li>
<li>Øvrige indholdsstoffer: natriumcitrat, koncentreret saltsyre, natriumhydroxid, vand til 
injektionsvæsker (se punkt 2 "Axumin indeholder natrium"). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Axumin er en klar, farveløs injektionsvæske, der leveres i et 10 ml eller 15 ml hætteglas. </p>
<p>Axumin 1.600 MBq/ml injektionsvæske, opløsning 
Et flerdosishætteglas indeholder 1-10 ml injektionsvæske svarende til 1.600-16.000 MBq på datoen og 
ToC. </p>
<p>Axumin 3.200 MBq/ml injektionsvæske, opløsning 
Et flerdosishætteglas indeholder 1-10 ml injektionsvæske svarende til 3.200-32.000 MBq på datoen og 
ToC. </p>
<p>Pakningsstørrelse: 1 hætteglas. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Blue Earth Diagnostics Ireland Ltd, 6th Floor, 2 Grand Canal Square, Dublin 2, Irland </p>
<p>Fremstiller 
Seibersdorf Labor GmbH, 2444 Seibersdorf, Østrig. </p>
<p>Norsk medisinsk syklotronsenter AS, 0372 Oslo, Norge. </p>
<p>Nucleis SA, 4000 Liège, Belgien. </p>
<p>Advanced Accelerator Applications Molecular Imaging Italy S.r.l., 47014 Meldola (FC), Italien </p>
<p>Synektik Pharma Sp. z o.o., 96-320 Mszczonów, Polen </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. </p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Det fulde produktresumé for Axumin er vedlagt pakningen som separat dokument for at give 
sundhedspersonalet yderligere videnskabelige og praktiske oplysninger om anvendelse og 
administration af dette radioaktive lægemiddel. 
Læs produktresuméet [produktresuméet skal inkluderes i pakningen]. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-e7c357e85455d1fe389fd3b297f16867
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for axumin Package Leaflet for language en"
Description: "ePI document Bundle for axumin Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e7c357e85455d1fe389fd3b297f16867"
* entry[0].resource = composition-en-e7c357e85455d1fe389fd3b297f16867

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe7c357e85455d1fe389fd3b297f16867"
* entry[=].resource = mpe7c357e85455d1fe389fd3b297f16867
                            
                    
Instance: bundlepackageleaflet-da-e7c357e85455d1fe389fd3b297f16867
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for axumin Package Leaflet for language da"
Description: "ePI document Bundle for axumin Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e7c357e85455d1fe389fd3b297f16867"
* entry[0].resource = composition-da-e7c357e85455d1fe389fd3b297f16867

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe7c357e85455d1fe389fd3b297f16867"
* entry[=].resource = mpe7c357e85455d1fe389fd3b297f16867
                            
                    



Instance: mpe7c357e85455d1fe389fd3b297f16867
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Axumin 1,600 MBq/mL solution for injection"
Description: "Axumin 1,600 MBq/mL solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1186/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Axumin 1,600 MBq/mL solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: e7c357e85455d1fe389fd3b297f16867ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "axumin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with axumin"

* subject = Reference(mpc8dd0ed09610078bf6d788aa5df84324)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#axumin "axumin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e7c357e85455d1fe389fd3b297f16867) // axumin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e7c357e85455d1fe389fd3b297f16867) // axumin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e7c357e85455d1fe389fd3b297f16867
InstanceOf: List

* insert e7c357e85455d1fe389fd3b297f16867ListRuleset
    